Teva Pharmaceutical has signed an agreement with Nanolek, a Moscow, Russia-based biopharmaceutical company, to transfer production of a number of sterile injectable products to Nanolek’s site in Russia. The transfer of production will include the creation of additional jobs, additional training of specialists, the transfer of technologies, including the output quality control, and the transfer of intellectual property rights. .

Production of the sterile injectable products will be based on the active pharmaceutical ingredients that Teva will produce at Nanolek’s facility in Yaroslavl, Russia, beginning with the local production of glatiramer acetate, the active ingredient in Teva’s top-selling drug, Copaxone, which is used for treating relapsing forms of multiple sclerosis. Glatiramer acetate is included in Russia’s vital and essential drugs list. The first commercial shipment of the finished dosage form is planned for the second half of 2017. Access to the full cycle of production for glatiramer acetate is expected in the fourth quarter of 2018.

Source: Nanolek